Free tool
FAERS Monitor: Opdualag
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761234 or its brand name (Opdualag, Nivolumab, Relatlimab-Rmbw). Reports on generic versions are filed under their own applications.
Reports
515
Serious
342
66% of reports
Hospitalization
112
Death reported
107
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death76
- off label use60
- malignant neoplasm progression35
- fatigue19
- myocarditis19
- product storage error19
- product dose omission issue15
- adverse event13
- colitis13
- rash13
- diarrhoea12
- myasthenia gravis12
- acute kidney injury9
- headache9
- hypothyroidism9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2022 | 46 |
| 2023 | 111 |
| 2024 | 106 |
| 2025 | 134 |
| 2026 | 117 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,644 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myocarditisSignal | 19 | 67.8 | 43.6 | 1,183 |
| myasthenia gravisSignal | 12 | 60.8 | 34.7 | 646 |
| colitisSignal | 13 | 14.0 | 8.2 | 145 |
| malignant neoplasm progressionSignal | 35 | 14.0 | 10.1 | 410 |
| hypothyroidismSignal | 9 | 11.5 | 6.0 | 76 |
| product storage errorSignal | 19 | 8.9 | 5.7 | 125 |
| adverse eventSignal | 13 | 5.8 | 3.4 | 47 |
| deathSignal | 76 | 3.6 | 2.9 | 146 |
| off label useSignal | 60 | 2.8 | 2.2 | 70 |
| acute kidney injurySignal | 9 | 2.4 | 1.3 | 6 |
| product dose omission issueSignal | 15 | 2.1 | 1.3 | 8 |
| rash | 13 | 1.2 | 0.7 | 0 |
| fatigue | 19 | 1.0 | 0.6 | 0 |
| diarrhoea | 12 | 0.8 | 0.4 | 1 |
| headache | 9 | 0.6 | 0.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.